Summary
We examined CEA and CA 19-9 in serum samples of 43 patients with colorectal adenocarcinoma in a follow-up programme ranging from 1 month to 5 years after curative surgery. In 10 patients with confirmed recurrence, CA 19-9 and/or CEA were positive prior to or at the time of recurrence. For these 10 patients CEA demonstrated a greater sensitivity, concurring in all 10 cases, than CA 19-9 which concurred in only 4 cases. In 33 patients with no objective evidence of disease CA 19-9 was consistently negative, while CEA was positive in four cases. Our studies, even though based on a limited number of case histories, suggest that these two antibodies are particularly useful when studied in association: the greater sensitivity of CEA is complemented by the specificity of CA 19-9.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowshi H (1982) Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 42: 4820–4823
Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, Rake B, Space S, Westrick B, Schoemaker H, Zurayski VRJr (1983) Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19–9. Clin Chem 29 /3: 549–552
Del Villano BC, Zurawski VCJr (1983) The carbohydrate antigenic determinant 19–9 (CA 19–9): a monoclonal antibody defined tumor marker. In: Immunodiagnostics. Alan R Liss, Inc, New York, pp 269–282
Fucini C, Tommasi M, Cardona G, Malatantis G, Panichi S, Bettini U (1983) Limitations of CEA monitoring as a guide to second-look surgery in colorectal cancer followup. Tumori 69: 359–364
Herlyn M (1984) Detection of tumor-associated antigen in sera of patients with early gastrointestinal tract malignancies. In: Chatal IF, Douis M (eds) Anticorps monoclonaux en cancérologie. Nantes, pp 21–23
Koprowski K, Steplewshi Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5: 957–971
Koprowski H, Sears HF, Herlyn M, Steplevski Z (1981) Sera from patients with adenocarcinoma of the colon inhibit binding of a monoclonal antibody to colon carcinoma cells. Science 212: 53–55
Magnani J, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V (1982) The antigen of a tumor-specific monoclonal antibody is a ganglioside containing sialylated lacto-Nfucopentaose II. J Biol Chem 257: 14365–14369
Magnani JL, Steplewski Z, Koprowski H, Ginsburg V (1983) Identification of the gastrointestinal and pancreatic cancer-associated as a mucin. Cancer Res 43: 5489–5492
Ritts REJr, Del Villano BC, GO VLW, Herberman RB, Klug TL Zurawski VR, Jr (1984) Initial clinical evaluation of an immunoradiometric assay for CA 19–9 using the NCI serum bank. Int J Cancer 33: 339–345
Sears HF, Herlyn M, Del Villano B, Steplevski Z, Koprowski H (1982) Monoclonal antibody detection of a circulating tumor-associated antigen II. A longitudinal valuation of patients with colorectal cancer. J Clin Immunol 2: 141–149
Thirion B (1984) Intérêt clinique du marqueur tumoral CA 19–9: résultats d’une étude multicentrique. In: Chatal IC, Douis M (eds) Anticorps monoclonaux en cancérologie. Nantes, pp 25–34
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt
About this paper
Cite this paper
Tommasi, M., Fantappiè, B., Fucini, C., Malatantis, G. (1987). CA 19-9 in the follow-up of colorectal cancer. In: Wüst, G. (eds) Tumormarker. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-88539-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-88539-6_5
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-642-88540-2
Online ISBN: 978-3-642-88539-6
eBook Packages: Springer Book Archive